Group 1 - The core viewpoint of the news is that Beijing Baipusi Biotechnology Co., Ltd. experienced a decline in stock price, with a drop of 5.02% to 58.65 CNY per share, and a total market capitalization of 9.844 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - A fund under Bank of China Securities holds a significant position in Baipusi, with the Bank of China Health Industry Mixed Fund (002938) owning 99,000 shares, representing 4.48% of the fund's net value, making it the seventh-largest holding [2] Group 2 - The Bank of China Health Industry Mixed Fund (002938) has a total asset size of 158 million CNY and has achieved a year-to-date return of 58.86%, ranking 653 out of 8172 in its category [2] - The fund manager, Li Mingwei, has been in charge for 2 years and 215 days, with the best and worst fund returns during his tenure both being 4.82% [3]